 Samuel Dominguez
Concepts (559)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 26 | 2023 | 160 | 8.400 |
Why?
| | Respiratory Tract Infections | 21 | 2023 | 321 | 5.360 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 18 | 2022 | 76 | 4.980 |
Why?
| | Disease Outbreaks | 20 | 2023 | 309 | 3.890 |
Why?
| | Enterovirus D, Human | 14 | 2023 | 72 | 3.850 |
Why?
| | Myelitis | 11 | 2019 | 88 | 3.380 |
Why?
| | Enterovirus | 11 | 2019 | 72 | 3.070 |
Why?
| | Molecular Diagnostic Techniques | 9 | 2021 | 91 | 2.970 |
Why?
| | Coronavirus | 10 | 2015 | 40 | 2.950 |
Why?
| | Meningitis | 8 | 2022 | 74 | 2.940 |
Why?
| | Multiplex Polymerase Chain Reaction | 10 | 2023 | 45 | 2.920 |
Why?
| | Influenza, Human | 13 | 2023 | 546 | 2.830 |
Why?
| | Child, Preschool | 69 | 2023 | 9123 | 2.570 |
Why?
| | Encephalitis | 11 | 2022 | 127 | 2.470 |
Why?
| | Child | 93 | 2023 | 18466 | 2.370 |
Why?
| | Gastroenteritis | 5 | 2023 | 65 | 2.280 |
Why?
| | Anti-Infective Agents | 5 | 2022 | 225 | 2.250 |
Why?
| | Infant | 53 | 2023 | 7966 | 2.170 |
Why?
| | Influenza A Virus, H1N1 Subtype | 7 | 2020 | 139 | 1.980 |
Why?
| | Immunoglobulins, Intravenous | 6 | 2020 | 122 | 1.970 |
Why?
| | Feces | 9 | 2023 | 373 | 1.960 |
Why?
| | Central Nervous System Viral Diseases | 4 | 2019 | 63 | 1.950 |
Why?
| | Neuromuscular Diseases | 4 | 2019 | 89 | 1.890 |
Why?
| | Diarrhea | 6 | 2023 | 171 | 1.840 |
Why?
| | Colorado | 37 | 2023 | 4099 | 1.830 |
Why?
| | Paralysis | 4 | 2018 | 67 | 1.690 |
Why?
| | Coronavirus Infections | 9 | 2020 | 334 | 1.630 |
Why?
| | Nervous System Diseases | 5 | 2020 | 253 | 1.600 |
Why?
| | Infliximab | 4 | 2019 | 94 | 1.540 |
Why?
| | Hospitals, Pediatric | 11 | 2021 | 477 | 1.500 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 36 | 1.450 |
Why?
| | Clostridium Infections | 5 | 2020 | 56 | 1.440 |
Why?
| | Simplexvirus | 3 | 2020 | 81 | 1.420 |
Why?
| | Humans | 140 | 2023 | 115219 | 1.420 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 90 | 1.370 |
Why?
| | Retrospective Studies | 38 | 2023 | 12596 | 1.280 |
Why?
| | Epidemiological Monitoring | 3 | 2020 | 48 | 1.240 |
Why?
| | Pandemics | 11 | 2023 | 1323 | 1.240 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2023 | 60 | 1.230 |
Why?
| | Intensive Care Units, Pediatric | 4 | 2021 | 147 | 1.220 |
Why?
| | Stevens-Johnson Syndrome | 3 | 2017 | 34 | 1.210 |
Why?
| | Male | 80 | 2023 | 55811 | 1.210 |
Why?
| | Anti-Bacterial Agents | 14 | 2023 | 1481 | 1.200 |
Why?
| | Bacteremia | 3 | 2019 | 159 | 1.200 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2023 | 97 | 1.190 |
Why?
| | Chiroptera | 4 | 2014 | 50 | 1.170 |
Why?
| | Polymerase Chain Reaction | 12 | 2023 | 1000 | 1.170 |
Why?
| | Bacterial Infections | 2 | 2020 | 219 | 1.160 |
Why?
| | Nasopharynx | 5 | 2023 | 63 | 1.140 |
Why?
| | Picornaviridae Infections | 5 | 2019 | 30 | 1.130 |
Why?
| | Spike Glycoprotein, Coronavirus | 8 | 2022 | 93 | 1.120 |
Why?
| | Female | 72 | 2023 | 59717 | 1.040 |
Why?
| | Communicable Diseases | 2 | 2017 | 130 | 1.000 |
Why?
| | Hospitalization | 14 | 2023 | 1754 | 0.960 |
Why?
| | Child, Hospitalized | 2 | 2023 | 39 | 0.920 |
Why?
| | Otitis Media | 2 | 2023 | 142 | 0.910 |
Why?
| | Adolescent | 39 | 2021 | 17887 | 0.900 |
Why?
| | RNA, Viral | 10 | 2020 | 567 | 0.900 |
Why?
| | Antiviral Agents | 6 | 2020 | 647 | 0.890 |
Why?
| | Bacteria | 6 | 2023 | 728 | 0.870 |
Why?
| | Coronaviridae | 2 | 2014 | 3 | 0.850 |
Why?
| | Parechovirus | 3 | 2019 | 7 | 0.830 |
Why?
| | Drug Resistance, Bacterial | 3 | 2022 | 155 | 0.820 |
Why?
| | Infant, Newborn | 17 | 2021 | 5052 | 0.790 |
Why?
| | Blood Culture | 1 | 2021 | 9 | 0.780 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 87 | 0.780 |
Why?
| | Nervous System Malformations | 1 | 2022 | 34 | 0.770 |
Why?
| | Rhinovirus | 5 | 2017 | 41 | 0.770 |
Why?
| | Virus Cultivation | 2 | 2018 | 25 | 0.750 |
Why?
| | Enteropathogenic Escherichia coli | 1 | 2020 | 1 | 0.740 |
Why?
| | Enterotoxigenic Escherichia coli | 1 | 2020 | 3 | 0.740 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.740 |
Why?
| | Osteomyelitis | 2 | 2020 | 103 | 0.730 |
Why?
| | Hospitals | 4 | 2021 | 582 | 0.730 |
Why?
| | Cross Infection | 3 | 2019 | 199 | 0.720 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.720 |
Why?
| | Adenoviridae Infections | 2 | 2023 | 15 | 0.700 |
Why?
| | Escherichia coli Infections | 1 | 2020 | 100 | 0.700 |
Why?
| | Acyclovir | 1 | 2020 | 100 | 0.680 |
Why?
| | Serratia Infections | 1 | 2019 | 6 | 0.680 |
Why?
| | Serratia marcescens | 1 | 2019 | 12 | 0.680 |
Why?
| | Receptors, Virus | 3 | 2017 | 75 | 0.660 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 21 | 0.660 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 29 | 0.660 |
Why?
| | Drug Utilization | 2 | 2017 | 167 | 0.660 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 13 | 0.660 |
Why?
| | Equipment Contamination | 1 | 2019 | 54 | 0.660 |
Why?
| | Antimicrobial Stewardship | 2 | 2020 | 94 | 0.660 |
Why?
| | Syringes | 1 | 2019 | 41 | 0.650 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 5 | 0.650 |
Why?
| | Pneumonia, Mycoplasma | 2 | 2017 | 30 | 0.650 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 48 | 0.640 |
Why?
| | Kingella kingae | 1 | 2018 | 8 | 0.640 |
Why?
| | Steroids | 1 | 2019 | 147 | 0.640 |
Why?
| | Coronary Vessels | 2 | 2018 | 230 | 0.640 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 342 | 0.640 |
Why?
| | Adenoviridae | 3 | 2023 | 184 | 0.640 |
Why?
| | Herpes Simplex | 2 | 2018 | 88 | 0.630 |
Why?
| | Enterovirus A, Human | 1 | 2018 | 12 | 0.630 |
Why?
| | Fluoxetine | 1 | 2018 | 46 | 0.620 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 65 | 0.610 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 182 | 0.610 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2017 | 14 | 0.590 |
Why?
| | Immunologic Factors | 1 | 2019 | 221 | 0.580 |
Why?
| | Viruses | 5 | 2022 | 94 | 0.570 |
Why?
| | Escherichia coli | 1 | 2020 | 720 | 0.560 |
Why?
| | Time Factors | 10 | 2021 | 6157 | 0.560 |
Why?
| | Seasons | 6 | 2023 | 448 | 0.560 |
Why?
| | Sensitivity and Specificity | 8 | 2023 | 1717 | 0.550 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 300 | 0.550 |
Why?
| | Osteoarthritis | 1 | 2018 | 172 | 0.540 |
Why?
| | Phylogeny | 9 | 2016 | 796 | 0.540 |
Why?
| | Viral Tropism | 2 | 2015 | 24 | 0.530 |
Why?
| | Genome, Viral | 3 | 2016 | 119 | 0.530 |
Why?
| | Molecular Epidemiology | 2 | 2017 | 63 | 0.530 |
Why?
| | Catheter-Related Infections | 1 | 2016 | 60 | 0.520 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 39 | 0.520 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 288 | 0.520 |
Why?
| | Catheterization, Central Venous | 1 | 2016 | 81 | 0.510 |
Why?
| | Adenovirus Infections, Human | 1 | 2015 | 12 | 0.500 |
Why?
| | Bacterial Typing Techniques | 1 | 2015 | 41 | 0.500 |
Why?
| | Calcitonin | 1 | 2015 | 23 | 0.500 |
Why?
| | Caliciviridae Infections | 1 | 2015 | 17 | 0.490 |
Why?
| | Muscle Hypotonia | 1 | 2015 | 31 | 0.490 |
Why?
| | Rotavirus Infections | 1 | 2015 | 50 | 0.480 |
Why?
| | Whole Genome Sequencing | 1 | 2015 | 96 | 0.480 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.470 |
Why?
| | Motor Neurons | 1 | 2016 | 212 | 0.460 |
Why?
| | Coronaviridae Infections | 1 | 2014 | 3 | 0.460 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 607 | 0.460 |
Why?
| | Rubulavirus Infections | 1 | 2013 | 2 | 0.460 |
Why?
| | United States | 17 | 2022 | 12256 | 0.450 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 138 | 0.440 |
Why?
| | Fever | 6 | 2022 | 281 | 0.440 |
Why?
| | Prevalence | 6 | 2020 | 2257 | 0.430 |
Why?
| | Neuraminidase | 3 | 2020 | 22 | 0.430 |
Why?
| | Sepsis | 1 | 2018 | 508 | 0.420 |
Why?
| | Sequence Analysis, DNA | 8 | 2019 | 728 | 0.420 |
Why?
| | Coronavirus NL63, Human | 1 | 2012 | 3 | 0.420 |
Why?
| | Metagenomics | 5 | 2021 | 131 | 0.410 |
Why?
| | Streptococcus pneumoniae | 2 | 2023 | 134 | 0.410 |
Why?
| | Betacoronavirus | 3 | 2020 | 253 | 0.410 |
Why?
| | Cohort Studies | 9 | 2022 | 4917 | 0.400 |
Why?
| | Viral Envelope Proteins | 1 | 2012 | 74 | 0.400 |
Why?
| | Case-Control Studies | 8 | 2020 | 3023 | 0.380 |
Why?
| | Recombination, Genetic | 1 | 2012 | 176 | 0.380 |
Why?
| | Genotype | 3 | 2014 | 1781 | 0.380 |
Why?
| | Acute Disease | 6 | 2023 | 918 | 0.380 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 138 | 0.380 |
Why?
| | Genetic Variation | 2 | 2014 | 876 | 0.370 |
Why?
| | Young Adult | 16 | 2021 | 10519 | 0.370 |
Why?
| | Streptococcal Infections | 2 | 2023 | 127 | 0.370 |
Why?
| | Cluster Analysis | 5 | 2021 | 458 | 0.360 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 977 | 0.360 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 15 | 0.350 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 538 | 0.350 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 429 | 0.350 |
Why?
| | Critical Care | 4 | 2021 | 476 | 0.340 |
Why?
| | Neoplasms | 3 | 2023 | 2106 | 0.320 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 4419 | 0.320 |
Why?
| | Virus Internalization | 4 | 2017 | 40 | 0.310 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.300 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2797 | 0.300 |
Why?
| | Immunity, Innate | 1 | 2013 | 723 | 0.300 |
Why?
| | Mycoplasma pneumoniae | 2 | 2017 | 28 | 0.290 |
Why?
| | Diagnosis, Differential | 7 | 2020 | 1356 | 0.280 |
Why?
| | Treatment Outcome | 7 | 2020 | 9151 | 0.280 |
Why?
| | Mycoplasma hominis | 1 | 2006 | 4 | 0.280 |
Why?
| | Streptococcus pyogenes | 2 | 2023 | 30 | 0.280 |
Why?
| | Virus Diseases | 1 | 2008 | 196 | 0.270 |
Why?
| | Endocarditis, Bacterial | 1 | 2006 | 36 | 0.270 |
Why?
| | Murine hepatitis virus | 2 | 2016 | 15 | 0.260 |
Why?
| | Algorithms | 3 | 2023 | 1488 | 0.260 |
Why?
| | Prospective Studies | 5 | 2022 | 6245 | 0.260 |
Why?
| | Enzyme Inhibitors | 3 | 2020 | 753 | 0.250 |
Why?
| | Immunization | 2 | 2004 | 401 | 0.250 |
Why?
| | Paraplegia | 2 | 2015 | 52 | 0.240 |
Why?
| | Methicillin Resistance | 1 | 2004 | 18 | 0.240 |
Why?
| | Apolipoproteins E | 3 | 1999 | 80 | 0.230 |
Why?
| | Global Health | 2 | 2021 | 288 | 0.230 |
Why?
| | Cellulitis | 1 | 2004 | 45 | 0.230 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 441 | 0.230 |
Why?
| | Coinfection | 2 | 2022 | 120 | 0.230 |
Why?
| | Haemophilus influenzae type b | 1 | 2003 | 10 | 0.230 |
Why?
| | Meningitis, Haemophilus | 1 | 2003 | 6 | 0.230 |
Why?
| | Risk Factors | 8 | 2021 | 8658 | 0.230 |
Why?
| | Haemophilus Vaccines | 1 | 2003 | 27 | 0.220 |
Why?
| | Haemophilus Infections | 1 | 2003 | 28 | 0.220 |
Why?
| | Medical Oncology | 2 | 2023 | 227 | 0.220 |
Why?
| | Antigens, Viral | 3 | 2020 | 176 | 0.220 |
Why?
| | Clindamycin | 2 | 2018 | 12 | 0.220 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 48 | 0.220 |
Why?
| | Polysaccharides, Bacterial | 1 | 2003 | 66 | 0.220 |
Why?
| | Clinical Laboratory Techniques | 2 | 2020 | 87 | 0.210 |
Why?
| | Incidence | 3 | 2021 | 2324 | 0.210 |
Why?
| | Coronavirus 229E, Human | 1 | 2022 | 4 | 0.210 |
Why?
| | Logistic Models | 2 | 2018 | 1841 | 0.210 |
Why?
| | Metapneumovirus | 1 | 2022 | 12 | 0.210 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 60 | 0.210 |
Why?
| | Viral Load | 2 | 2021 | 405 | 0.200 |
Why?
| | Pharyngitis | 1 | 2022 | 23 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 4 | 2018 | 3128 | 0.200 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2020 | 42 | 0.200 |
Why?
| | North America | 2 | 2016 | 259 | 0.200 |
Why?
| | Lung | 1 | 2014 | 3595 | 0.190 |
Why?
| | Abdominal Pain | 2 | 2020 | 135 | 0.190 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 798 | 0.190 |
Why?
| | Brain Diseases | 2 | 2020 | 127 | 0.190 |
Why?
| | Meningoencephalitis | 2 | 2019 | 24 | 0.190 |
Why?
| | Lethargy | 1 | 2020 | 4 | 0.190 |
Why?
| | Length of Stay | 3 | 2020 | 951 | 0.180 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 21 | 0.180 |
Why?
| | Intestinal Diseases | 1 | 2020 | 29 | 0.180 |
Why?
| | Staphylococcus aureus | 1 | 2004 | 386 | 0.180 |
Why?
| | Arbovirus Infections | 1 | 2020 | 17 | 0.180 |
Why?
| | Meningitis, Viral | 1 | 2020 | 21 | 0.180 |
Why?
| | Peptide Fragments | 3 | 1999 | 668 | 0.180 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 19 | 0.180 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 928 | 0.180 |
Why?
| | Medical Records | 2 | 2018 | 155 | 0.180 |
Why?
| | Influenza Vaccines | 1 | 2005 | 496 | 0.180 |
Why?
| | Circulating MicroRNA | 1 | 2020 | 24 | 0.180 |
Why?
| | Staphylococcal Infections | 1 | 2004 | 337 | 0.180 |
Why?
| | Vomiting | 1 | 2020 | 124 | 0.170 |
Why?
| | Myositis | 1 | 2020 | 44 | 0.170 |
Why?
| | Heart Defects, Congenital | 1 | 2006 | 666 | 0.170 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 40 | 0.170 |
Why?
| | HIV Infections | 1 | 2014 | 2470 | 0.170 |
Why?
| | Arthritis, Infectious | 1 | 2020 | 49 | 0.170 |
Why?
| | Respiratory Tract Diseases | 1 | 2021 | 140 | 0.170 |
Why?
| | Coronary Aneurysm | 1 | 2019 | 11 | 0.170 |
Why?
| | Immunocompromised Host | 1 | 2021 | 196 | 0.170 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.170 |
Why?
| | Consciousness Disorders | 1 | 2019 | 19 | 0.170 |
Why?
| | Follow-Up Studies | 4 | 2017 | 4430 | 0.170 |
Why?
| | Receptors, Lipoprotein | 1 | 1999 | 2 | 0.170 |
Why?
| | Amino Acid Sequence | 5 | 2016 | 1990 | 0.160 |
Why?
| | Animals | 14 | 2022 | 31884 | 0.160 |
Why?
| | Disease Management | 2 | 2021 | 562 | 0.160 |
Why?
| | Hepatitis | 1 | 2019 | 45 | 0.160 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.160 |
Why?
| | Neurocysticercosis | 1 | 2018 | 6 | 0.160 |
Why?
| | Abdomen | 1 | 2019 | 104 | 0.160 |
Why?
| | Intensive Care Units | 2 | 2015 | 618 | 0.160 |
Why?
| | HEK293 Cells | 3 | 2016 | 590 | 0.160 |
Why?
| | Adult | 13 | 2023 | 30708 | 0.160 |
Why?
| | Immunoglobulin G | 2 | 2020 | 775 | 0.160 |
Why?
| | Antibodies, Viral | 3 | 2020 | 522 | 0.160 |
Why?
| | Epithelial Cells | 2 | 2015 | 956 | 0.160 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2552 | 0.150 |
Why?
| | Body Fluids | 1 | 2018 | 57 | 0.150 |
Why?
| | Vero Cells | 2 | 2015 | 63 | 0.150 |
Why?
| | Methyltransferases | 1 | 2018 | 61 | 0.150 |
Why?
| | Lipoproteins | 1 | 1999 | 160 | 0.150 |
Why?
| | Databases, Factual | 1 | 2023 | 1136 | 0.150 |
Why?
| | Prognosis | 2 | 2016 | 3336 | 0.150 |
Why?
| | Sequence Alignment | 2 | 2016 | 325 | 0.150 |
Why?
| | Heparin | 1 | 2019 | 222 | 0.150 |
Why?
| | Canada | 2 | 2016 | 323 | 0.150 |
Why?
| | Receptors, Immunologic | 1 | 1999 | 201 | 0.150 |
Why?
| | Chronic Disease | 1 | 2023 | 1593 | 0.150 |
Why?
| | Chlamydophila pneumoniae | 1 | 2017 | 11 | 0.150 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 13 | 0.150 |
Why?
| | Mycoplasma Infections | 1 | 2017 | 13 | 0.150 |
Why?
| | Antibodies, Monoclonal | 2 | 2015 | 1268 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2020 | 161 | 0.150 |
Why?
| | Inflammation | 2 | 2018 | 2485 | 0.150 |
Why?
| | Intubation, Gastrointestinal | 1 | 2017 | 53 | 0.150 |
Why?
| | Stomach | 1 | 2017 | 101 | 0.150 |
Why?
| | Specimen Handling | 1 | 2018 | 155 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 177 | 0.140 |
Why?
| | Mouth Mucosa | 1 | 2017 | 79 | 0.140 |
Why?
| | Seizures | 1 | 2020 | 341 | 0.140 |
Why?
| | Movement Disorders | 1 | 2017 | 46 | 0.140 |
Why?
| | Gastrostomy | 1 | 2017 | 89 | 0.140 |
Why?
| | Urban Population | 1 | 2019 | 402 | 0.140 |
Why?
| | Electromyography | 2 | 2017 | 326 | 0.140 |
Why?
| | Vaccination | 1 | 2005 | 1205 | 0.140 |
Why?
| | Densovirus | 1 | 2016 | 2 | 0.140 |
Why?
| | Muscular Diseases | 1 | 2017 | 106 | 0.140 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 14 | 0.140 |
Why?
| | Middle East Respiratory Syndrome Coronavirus | 1 | 2016 | 5 | 0.140 |
Why?
| | Encephalomyelitis | 1 | 2016 | 9 | 0.140 |
Why?
| | Dendritic Spines | 1 | 2016 | 49 | 0.130 |
Why?
| | Lyme Disease | 1 | 2016 | 32 | 0.130 |
Why?
| | Bacterial Proteins | 2 | 2018 | 736 | 0.130 |
Why?
| | Syncope | 1 | 2016 | 37 | 0.130 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.130 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.130 |
Why?
| | Still's Disease, Adult-Onset | 1 | 1995 | 4 | 0.130 |
Why?
| | Rural Population | 1 | 2019 | 447 | 0.130 |
Why?
| | Stomach Ulcer | 1 | 1995 | 9 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2014 | 3897 | 0.130 |
Why?
| | Bradycardia | 1 | 2016 | 48 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2806 | 0.130 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 27 | 0.130 |
Why?
| | Early Diagnosis | 1 | 2016 | 218 | 0.130 |
Why?
| | Cephalosporins | 1 | 2015 | 26 | 0.130 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2015 | 14 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 372 | 0.130 |
Why?
| | Colonoscopy | 1 | 2017 | 204 | 0.130 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 17 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2023 | 831 | 0.130 |
Why?
| | Sapovirus | 1 | 2015 | 1 | 0.130 |
Why?
| | Peritonitis | 1 | 1995 | 76 | 0.120 |
Why?
| | Rotavirus | 1 | 2015 | 22 | 0.120 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 133 | 0.120 |
Why?
| | Virus Shedding | 1 | 2015 | 39 | 0.120 |
Why?
| | Norovirus | 1 | 2015 | 23 | 0.120 |
Why?
| | RNA Viruses | 1 | 2015 | 28 | 0.120 |
Why?
| | Recurrence | 1 | 2017 | 952 | 0.120 |
Why?
| | Particulate Matter | 1 | 2016 | 185 | 0.120 |
Why?
| | Immunoglobulins | 1 | 2015 | 143 | 0.120 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 93 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 639 | 0.120 |
Why?
| | Biopsy | 1 | 2018 | 1050 | 0.120 |
Why?
| | Health Resources | 1 | 2016 | 122 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 520 | 0.120 |
Why?
| | Echocardiography | 2 | 2019 | 563 | 0.120 |
Why?
| | Cost of Illness | 1 | 2016 | 255 | 0.120 |
Why?
| | Bacterial Shedding | 1 | 2014 | 2 | 0.120 |
Why?
| | Microscopy, Electron | 1 | 2015 | 410 | 0.120 |
Why?
| | Zanamivir | 1 | 2014 | 1 | 0.120 |
Why?
| | Infection Control | 1 | 2015 | 135 | 0.120 |
Why?
| | Dogs | 1 | 2015 | 340 | 0.120 |
Why?
| | Oseltamivir | 1 | 2014 | 11 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2016 | 386 | 0.110 |
Why?
| | Parainfluenza Virus 4, Human | 1 | 2013 | 2 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 299 | 0.110 |
Why?
| | Molecular Typing | 1 | 2013 | 18 | 0.110 |
Why?
| | Drug Therapy, Combination | 2 | 2013 | 959 | 0.110 |
Why?
| | Disease Reservoirs | 1 | 2013 | 18 | 0.110 |
Why?
| | Giant Cells | 1 | 2013 | 21 | 0.110 |
Why?
| | Pediatrics | 3 | 2020 | 986 | 0.110 |
Why?
| | Brazil | 1 | 2013 | 92 | 0.110 |
Why?
| | Mexico | 1 | 2013 | 163 | 0.110 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 251 | 0.110 |
Why?
| | Membrane Proteins | 1 | 1999 | 1019 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 163 | 0.110 |
Why?
| | Biomarkers | 3 | 2021 | 3421 | 0.110 |
Why?
| | Oxygen | 2 | 2023 | 855 | 0.110 |
Why?
| | Environmental Exposure | 1 | 2016 | 377 | 0.110 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 35 | 0.100 |
Why?
| | Neuroimaging | 1 | 2014 | 251 | 0.100 |
Why?
| | Brain | 3 | 2018 | 2378 | 0.100 |
Why?
| | Glucocorticoids | 2 | 2013 | 539 | 0.100 |
Why?
| | Temperature | 1 | 2015 | 578 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 207 | 0.100 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 221 | 0.100 |
Why?
| | Treatment Failure | 1 | 2013 | 332 | 0.100 |
Why?
| | Inpatients | 1 | 2015 | 378 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 366 | 0.100 |
Why?
| | Critical Illness | 1 | 2016 | 645 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 502 | 0.100 |
Why?
| | Illinois | 2 | 2015 | 37 | 0.090 |
Why?
| | Age Factors | 2 | 2010 | 2900 | 0.090 |
Why?
| | Peptides | 1 | 2016 | 849 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 106 | 0.090 |
Why?
| | Intestines | 1 | 2013 | 322 | 0.090 |
Why?
| | Aspirin | 1 | 2013 | 324 | 0.090 |
Why?
| | Middle Aged | 10 | 2020 | 26872 | 0.090 |
Why?
| | Macrophages, Alveolar | 1 | 2013 | 351 | 0.090 |
Why?
| | Community-Acquired Infections | 2 | 2017 | 141 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2013 | 676 | 0.080 |
Why?
| | Cell Line | 5 | 2017 | 2645 | 0.080 |
Why?
| | Ear Diseases | 1 | 1988 | 13 | 0.080 |
Why?
| | Cholesteatoma | 1 | 1988 | 11 | 0.080 |
Why?
| | Cleft Palate | 1 | 1988 | 45 | 0.080 |
Why?
| | Liver Diseases | 1 | 2011 | 263 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1477 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2008 | 151 | 0.070 |
Why?
| | Lipoproteins, LDL | 2 | 1999 | 129 | 0.070 |
Why?
| | Patient Admission | 1 | 2008 | 175 | 0.070 |
Why?
| | Cross-Over Studies | 2 | 2019 | 442 | 0.070 |
Why?
| | Odds Ratio | 2 | 2021 | 958 | 0.070 |
Why?
| | Immunoassay | 1 | 2006 | 95 | 0.060 |
Why?
| | Mice | 6 | 2022 | 14934 | 0.060 |
Why?
| | Population Surveillance | 1 | 2008 | 392 | 0.060 |
Why?
| | Chicago | 1 | 2004 | 45 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2344 | 0.060 |
Why?
| | Models, Molecular | 3 | 2017 | 1379 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 2 | 2020 | 501 | 0.060 |
Why?
| | Hepacivirus | 1 | 2006 | 233 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1816 | 0.060 |
Why?
| | Bacterial Capsules | 1 | 2003 | 28 | 0.060 |
Why?
| | Base Sequence | 1 | 2007 | 2120 | 0.060 |
Why?
| | Computational Biology | 2 | 2019 | 532 | 0.050 |
Why?
| | Hepatitis C | 1 | 2006 | 228 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 246 | 0.050 |
Why?
| | Streptococcus | 1 | 2023 | 23 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2023 | 315 | 0.050 |
Why?
| | Minnesota | 1 | 2023 | 134 | 0.050 |
Why?
| | Respiratory System | 1 | 2023 | 138 | 0.050 |
Why?
| | Immunization Schedule | 1 | 2003 | 184 | 0.050 |
Why?
| | Heparin Lyase | 2 | 1999 | 4 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 623 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 19 | 0.050 |
Why?
| | Republic of Korea | 1 | 2021 | 27 | 0.050 |
Why?
| | New Zealand | 1 | 2021 | 41 | 0.050 |
Why?
| | Italy | 1 | 2021 | 92 | 0.050 |
Why?
| | History, 21st Century | 1 | 2022 | 161 | 0.050 |
Why?
| | Immunization Programs | 1 | 2003 | 206 | 0.050 |
Why?
| | Schools | 1 | 2004 | 400 | 0.050 |
Why?
| | Embryo, Mammalian | 2 | 1999 | 214 | 0.050 |
Why?
| | Monte Carlo Method | 1 | 2021 | 137 | 0.050 |
Why?
| | Aged | 4 | 2020 | 19135 | 0.050 |
Why?
| | Societies, Medical | 1 | 2005 | 680 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2021 | 61 | 0.050 |
Why?
| | Conserved Sequence | 2 | 1998 | 218 | 0.050 |
Why?
| | Oropharynx | 1 | 2020 | 36 | 0.050 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 24 | 0.050 |
Why?
| | Serologic Tests | 1 | 2020 | 49 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2020 | 73 | 0.040 |
Why?
| | Receptors, LDL | 2 | 1998 | 38 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 324 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 75 | 0.040 |
Why?
| | Discriminant Analysis | 1 | 2020 | 38 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 25 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 118 | 0.040 |
Why?
| | Chlorates | 1 | 1999 | 4 | 0.040 |
Why?
| | Immunocompetence | 1 | 2019 | 40 | 0.040 |
Why?
| | Health Personnel | 1 | 2005 | 575 | 0.040 |
Why?
| | Scavenger Receptors, Class B | 1 | 1999 | 9 | 0.040 |
Why?
| | Scavenger Receptors, Class A | 1 | 1999 | 9 | 0.040 |
Why?
| | Receptors, Scavenger | 1 | 1999 | 16 | 0.040 |
Why?
| | Egtazic Acid | 1 | 1999 | 44 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 779 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 152 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 18 | 0.040 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 104 | 0.040 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 7 | 0.040 |
Why?
| | Europe | 1 | 2020 | 336 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2019 | 83 | 0.040 |
Why?
| | Parasites | 1 | 2019 | 37 | 0.040 |
Why?
| | Lipoproteins, HDL | 1 | 1999 | 76 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 363 | 0.040 |
Why?
| | Lactams | 1 | 1998 | 18 | 0.040 |
Why?
| | Blood | 1 | 1999 | 97 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 229 | 0.040 |
Why?
| | Plasma | 1 | 2020 | 210 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 159 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2020 | 143 | 0.040 |
Why?
| | Child Health Services | 1 | 2020 | 176 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2020 | 298 | 0.040 |
Why?
| | Clinical Competence | 1 | 2005 | 904 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2018 | 292 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 130 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 247 | 0.040 |
Why?
| | Arboviruses | 1 | 2017 | 10 | 0.040 |
Why?
| | Headache | 1 | 2018 | 132 | 0.040 |
Why?
| | RNA | 1 | 2023 | 810 | 0.040 |
Why?
| | Fibroblasts | 2 | 1999 | 839 | 0.040 |
Why?
| | Genomics | 1 | 2022 | 641 | 0.040 |
Why?
| | Structural Homology, Protein | 1 | 2017 | 23 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 721 | 0.040 |
Why?
| | Contact Tracing | 1 | 2017 | 16 | 0.040 |
Why?
| | Genes, Bacterial | 1 | 2018 | 158 | 0.040 |
Why?
| | Models, Chemical | 1 | 1999 | 250 | 0.040 |
Why?
| | Bacterial Toxins | 1 | 2018 | 103 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 169 | 0.040 |
Why?
| | Administration, Oral | 1 | 2019 | 731 | 0.040 |
Why?
| | Epitope Mapping | 1 | 2017 | 51 | 0.040 |
Why?
| | Neural Conduction | 1 | 2017 | 79 | 0.040 |
Why?
| | Macrolides | 1 | 2017 | 56 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 387 | 0.040 |
Why?
| | Mutant Proteins | 1 | 2017 | 95 | 0.040 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2016 | 5 | 0.040 |
Why?
| | Atrophy | 1 | 2017 | 152 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2018 | 174 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 39 | 0.030 |
Why?
| | Eosinophilia | 1 | 2018 | 186 | 0.030 |
Why?
| | Pyramidal Cells | 1 | 2016 | 50 | 0.030 |
Why?
| | Urban Health | 1 | 2016 | 73 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1458 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2016 | 78 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 160 | 0.030 |
Why?
| | Membrane Fusion | 1 | 2016 | 39 | 0.030 |
Why?
| | Naproxen | 1 | 1995 | 11 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 116 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 207 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2019 | 476 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2017 | 405 | 0.030 |
Why?
| | Missouri | 1 | 2015 | 64 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 487 | 0.030 |
Why?
| | Prednisolone | 1 | 1995 | 77 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1860 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 317 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 250 | 0.030 |
Why?
| | Epitopes | 1 | 2017 | 436 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2016 | 147 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 133 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2015 | 111 | 0.030 |
Why?
| | Protein Binding | 2 | 2017 | 1898 | 0.030 |
Why?
| | Systole | 1 | 2015 | 173 | 0.030 |
Why?
| | Cough | 1 | 2015 | 107 | 0.030 |
Why?
| | beta Catenin | 1 | 2016 | 220 | 0.030 |
Why?
| | Cote d'Ivoire | 1 | 2014 | 8 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1188 | 0.030 |
Why?
| | Vietnam | 1 | 2014 | 21 | 0.030 |
Why?
| | Biodiversity | 1 | 2018 | 358 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 350 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 101 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 266 | 0.030 |
Why?
| | Gene Order | 1 | 2013 | 24 | 0.030 |
Why?
| | Dyspnea | 1 | 2015 | 218 | 0.030 |
Why?
| | California | 1 | 2015 | 364 | 0.030 |
Why?
| | Cell Membrane | 2 | 2013 | 681 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1214 | 0.030 |
Why?
| | Lentivirus | 1 | 2013 | 45 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2016 | 307 | 0.030 |
Why?
| | Trypsin | 1 | 2013 | 67 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2016 | 333 | 0.030 |
Why?
| | Synapses | 1 | 2016 | 330 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1397 | 0.030 |
Why?
| | Endosomes | 1 | 2013 | 124 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2016 | 437 | 0.030 |
Why?
| | Exanthema | 1 | 2013 | 77 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 512 | 0.030 |
Why?
| | Macrophages | 1 | 1999 | 1267 | 0.030 |
Why?
| | Gene Deletion | 1 | 2013 | 356 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2015 | 527 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1811 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 2011 | 42 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1082 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2011 | 87 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 89 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 2586 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2011 | 141 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 846 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 2981 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 1902 | 0.020 |
Why?
| | Iowa | 1 | 1988 | 24 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 5525 | 0.020 |
Why?
| | Mental Disorders | 1 | 2016 | 897 | 0.020 |
Why?
| | Otitis Media with Effusion | 1 | 1988 | 21 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1424 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1137 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 637 | 0.020 |
Why?
| | Capsid Proteins | 1 | 2008 | 69 | 0.020 |
Why?
| | Hepatitis C Antigens | 1 | 2006 | 1 | 0.020 |
Why?
| | Hepatitis C Antibodies | 1 | 2006 | 10 | 0.020 |
Why?
| | Viral Proteins | 1 | 2008 | 281 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 3350 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 2006 | 110 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 6358 | 0.010 |
Why?
| | Asthma | 1 | 2015 | 2051 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1998 | 135 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1998 | 126 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1998 | 325 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1998 | 503 | 0.010 |
Why?
| | Polysaccharide-Lyases | 1 | 1996 | 12 | 0.010 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 1998 | 238 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 195 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1036 | 0.010 |
Why?
| | Protein Conformation | 1 | 1996 | 811 | 0.010 |
Why?
| | Binding Sites | 1 | 1996 | 1173 | 0.010 |
Why?
| | Liver | 1 | 1996 | 1688 | 0.000 |
Why?
| | Rats | 1 | 1996 | 4980 | 0.000 |
Why?
|
|
Dominguez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|